Holen Sie sich die Stockscreener-App
10.05
0.20%
0.02
Handel nachbörslich:
10.05
Drugs Made In America Acquisition Corp Aktie (DMAA) Neueste Nachrichten
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Pfizer Inc. - Britannica
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Theratechnologies’ stock soars on disclosure of acquisition offer by U.S. company - Montreal Gazette
'I bought their dream': How a US company's huge land deal in Senegal went bust - Yahoo
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - StockTitan
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - The Manila Times
DRUGS MADE IN AMERICA ACQUISITION CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
India-based Syngene acquires its first US biologics site - Manufacturing Dive
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly and Company
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Forms Advisory Team to Pursue Pharmaceutical Business Acquisitions - Nasdaq
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
NewGen Issues Clarification on Press Release Titled 'NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025 - The Manila Times
Drugs Made In America Acquisition Corp. Announces Trading Options for Public Offering Units Starting February 25, 2025 - Nasdaq
Mink Ventures Completes Acquisition of Warren Ni, Cu, Co Patents - The Manila Times
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Corp. Secures Additional $30 Million in IPO as Underwriter Fully Exercises Overallotment Option - Nasdaq
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Trump wants to put tariffs on prescription drugs. Experts warn it could backfire. - Yahoo Finance
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
United Parcel Service (UPS) | History, Services, & Facts - Britannica
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering - The Manila Times
Drugs Made In America Acquisition Prices $200 Million IPO - MarketScreener
Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO - SPAC Insider
Bright Green Corporation Has Signed Agreement with Majority - GlobeNewswire
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC - Newsweek
How a Company Makes Millions Off a Hospital Program Meant to Help the Poor - The New York Times
How Trump’s Greenland demands could impact Ozempic costs - The Hill
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. - Johnson & Johnson
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk - Barron's
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Price Target at $7.20 - Defense World
2024 drug approvals: Small companies loom large with several key FDA nods - Fierce Pharma
Layoffs Continued Across Biopharma in 2024 - BioSpace
Bright Green enters into restructuring security agreement with Lynn Stockwell - Yahoo Finance
Bright Green (BGXX) Announces Major Restructuring: Founder Returns as CEO, Plans API Manufacturing Focus - Stock Titan
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval - Reuters
Dallas Entrepreneur Seeks to Build Nationwide Compounding Pharmacy Network - Dallas Innovates
7 Companies Owned by Pfizer - Investopedia
Top 10 Asthma Drug Companies | Provides Best Medicines - Market.us Media
FTC’s watchdog role in pharma mergers: Road bumps and the way forward - Norton Rose Fulbright
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal - FiercePharma
IPO Roundup: Drugs Made in America Acquisition, FBS Global and more (NYSEARCA:IPO) - Seeking Alpha
The top biotech deals of September 2024 - Labiotech.eu
BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda - Fierce Pharma
23andMe Is Sinking Fast. Can the Company Survive? - WIRED
How Many Stocks Are There in 2024? - Benzinga
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements - GlobeNewswire
FTC v Actavis and pricing practices spearhead rise in US pharmaceutical antitrust cases - Global Competition Review
We bought what’s needed to make millions of fentanyl pills–for $3,600 - Reuters
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs - Forbes
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market - BioSpace
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease | Eli Lilly and Company - Eli Lilly and Company
0.53%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):